Hot Pharma Stocks / Ideen / Blockbuster

  • Hot Pharma Stocks / Ideen / Blockbuster

    Acura Pharmaceuticals, Inc.

    (Public, NASDAQ:ACUR)


    netter tageschart, vlt geht noch mehr

  • Shopping Liste

    hier meine shopping Liste für heute (basierend auf niederschlagende resultate und somit schöne dips.)


    aufgepasst! watch it! than buy it! oder eben nicht.

    daytrading basis.


    HEV (vorsicht, könnte böse abdriften)

    0.729

    -0.051 (-6.60%)


    BSPM

    1.08

    -0.05 (-4.42%)


    ALXA (sehr gutes play. erholt sich zeitweise bis in die 1.60er)

    1.14

    -0.09 (-7.32%)


    RXII (they bring the news, you make the ca$h)

    1.02

    -0.07 (-6.42%)


    ELTP (machen immernoch keinen zaster, werden heute wiedr bestraft, rappeln sich aber jedes mal wieder auf)

    $0.10

    -0.008 (7.41%)


    thats it for now. gibt sicher noch 4-5 andere wo schnelle erholung sichtbar sein wird.

    alles daytrades freunde. auf 10% veränderung handeln.

    Handelnder Holländer

  • SGEN 15.30$

    U.S. Food And Drug Administration Accepts Filing Two Biologics License Applications For Seattle Genetics' Brentuximab Vedotin


    Quote:

    Quote


    Seattle Genetics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing two Biologics License Applications (BLAs) for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). The FDA administratively separated the original BLA submission and will act individually on the application for each indication. In addition, the FDA has granted a six-month priority review of both applications, and has established an action date of August 30, 2011 under the Prescription Drug User Fee Act (PDUFA). Priority review designation is assigned to drugs that, if approved, would address an unmet medical need for a serious or life-threatening condition. Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of Hodgkin lymphoma and ALCL. Seattle Genetics announced on February 28, 2011 that it had submitted a BLA for brentuximab vedotin based on results from both a pivotal trial in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic ALCL. The pivotal trial in Hodgkin lymphoma was conducted under a Special Protocol Assessment (SPA) with the FDA. Brentuximab vedotin has been granted orphan drug designation by the FDA for the treatment of Hodgkin lymphoma and ALCL.


    http://www.reuters.com/finance…s/SGEN.O/key-developments


    FDA Panel Backs Seattle Genetics Drug for Lymphoma


    Quote:


    Target Price

    Mean estimate : 17.70

    Median estimate : 18.00

    High estimate : 26.00

    Low estimate : 10.00


    Chart:


    [Blocked Image: http://img829.imageshack.us/img829/7172/sgen.th.png]


    bei 13.50$ und 14.00$ sind 2 offene gaps nach unten. Bei 19.00$ ist oben eins offen.

    Mit einem Panelvoting von 10-0 für Aproove, müsste Brentuximab sehr wahrscheinlich zugelassen werden. Ein SPA ist auch vorhanden. Die Frage ist nur was mit dem Aktienpreis sein wird? :) Wenn man sich die Preisziele anschaut sind wir im Moment etwa in der Mitte bei 15.30$ und es sind noch 2 Wochen bis zur Zulassung. Bear raid, nicht augeschlossen. Run up zu 19.00$ auch möglich. 20.00$ bei der Zulassung,könnte erreicht werden je nach Markt. Auf jeden Fall ist das wieder ein Event, der in den Terminkalender gehört.

    30. August 2011


    Hab im Moment keine Position.

    bubble gum?

  • Hot Pharma Stocks / Ideen / Blockbuster

    bin zu früh raus bei ALXA (1.26, rein bei 1.20 :lol: )

    crit happens!

    wennschon ein gewinn^^

    In den USA wird der Weg vom Tellerwäscher zum Millionär kürzer.

  • Yongye International Inc (Public, NASDAQ:YONG)

    zwar china, aber iwie doch interessant.


    4.55

    52 week 3.01 - 9.49


    Yongye International, Inc., formerly Yongye Biotechnology International, Inc.

    incorporated on December 12, 2006, through its primary operating subsidiary, Yongye Nongfeng, is engaged in the manufacturing, research and development and sale of fulvic acid-based liquid and powder nutrient compounds used in the agriculture industry in the People’s Republic of China (PRC). The Company manufactures and sells two principal products, which are plant product and animal product. The Company’s universal liquid plant product consists of its fulvic acid compound base mixed with additional nutrients that plants typically need to grow. It is applied to various types of crops by mixing with water and spraying directly on the plants, typically in conjunction with normal fertilizer and pesticide usage. Its animal product is a powder and consists of its fulvic acid base compound mixed with other nutrients and Chinese herbs.


    div. sachen in der pipe


    Experiment Summary of the Effect of

    Yongye Plant Nutrient on Tobacco


    Summary Report on the Demonstration of Potato Applied with Yongye Plant Nutrient

    .... http://www.yongyeintl.com/Publications.html


    bereits aufm markt;


    http://www.yongyeintl.com/Plant_Products.html


    -----


    Second Quarter 2011 Financial Highlights




    Revenue in the second quarter of 2011 increased 73.0% to $154.7 million from $89.4 million for the same period of 2010



    Gross profit increased 83.4% year-over-year to $91.8 million



    Income from operations increased 72.5% to $51.5 million



    Net income attributable to Yongye increased 63.1% to $39.5 million, or $0.77 per diluted share, compared to $24.2 million, or $0.54 per diluted share, in the same period last year



    Adjusted net income attributable to Yongye, which excludes non-cash expenses related to share-based compensation for management and independent directors, the amortization of the acquired Hebei customer list, and a change in the fair value of derivative liabilities, was $40.5 million, or $0.82 per diluted share, compared to $24.1 million, or $0.54 per diluted share, in the same period last year*


    ---


    Yongye International, Inc. Changes Exchange From OTC To NASDAQ-Stock Exchange

    Reuters Key Development - Sep 7, 2009


    ------


    ja ich bin eigetl. wegen folgendem darauf gekommen: :!:


    [Blocked Image: http://i52.tinypic.com/xbfh2e.jpg]

  • PATH 3.64$

    Die FDA müsste heute einen Zulassungsentscheid über NuPathes Migränepatch "Zelrix" veröffentlichen. Das Chancen/Risiko Verhältnis ist etwa 30/70, die Risiken überwiegen, NuPathe steht zum ersten Mal vor der FDA und hatte dieses Jahr ihr IPO. (so einen blöden Patch könnte man doch einfach zulassen, wenn interessierts, kauft doch eh keine Sau?) :)

    Der Inhaltsstoff des Patch ist Sumatriptan, ein zugelassenes, verschreibungspflichtiges Mittel gegen Migräne.


    http://de.wikipedia.org/wiki/Sumatriptan


    Sollte ein positiver Entscheid gefällt werden, kann man einen Preisanstieg um ca. 100%. auf über 7.00$ erwarten. Wedbush hat ein Kursziel von 20$ für PATH.

    Es ist aber mit einem CRL zu rechnen.


    http://img641.imageshack.us/img641/3753/paths.png


    Kursziele nach oben: 7-10$

    Kursziele nach unten: 1.65$-2.40$


    PATH hat einen Buchwert von 1.71$ und 2.41$ Cash per Aktie.


    http://finance.yahoo.com/q/ks?s=PATH+Key+Statistics


    Hab keine Posi im Moment.


    Update folgt...


    [Blocked Image: http://technicallyphilly.com/w…ploads/2009/09/Zelrix.png]

    [Blocked Image: http://www.flyingkitemedia.com…/Issue_04/Nupathe_FP1.jpg]


    http://www.nupathe.com/

    _____________________________________________________________________________


    [Blocked Image: http://4.bp.blogspot.com/-uz38…zhqbxhnbPSQ/s400/path.jpg]

    bubble gum?

  • Hot Pharma Stocks / Ideen / Blockbuster

    @ sharewatch hab gestern zur eröffnung verkauft, dachte nicht das es so weit rauf geht. bin trotzdem zufrieden EP 1.55$ VP 2.10$.

    normalerweise würde es nicht so hoch bouncen, wird wohl alles shortcovering sein vom 3.95$ high.

    bubble gum?

  • Hot Pharma Stocks / Ideen / Blockbuster

    Vagnum wrote:

    Quote
    @ sharewatch hab gestern zur eröffnung verkauft, dachte nicht das es so weit rauf geht. bin trotzdem zufrieden EP 1.55$ VP 2.10$.

    normalerweise würde es nicht so hoch bouncen, wird wohl alles shortcovering sein vom 3.95$ high.


    Gratuliere :!: Der positive Markt gestern hat dem Höhenflug zusätzlich geholfen.

  • Hot Pharma Stocks / Ideen / Blockbuster

    sharewatch wrote:

    Quote


    Gratuliere :!: Der positive Markt gestern hat dem Höhenflug zusätzlich geholfen.


    definitiv. der DOW ist jetzt bei 11500, mal seh was der *Path* von hier aus sein wird.;)

    bubble gum?

  • PATH

    FDA Requests Additional Information Regarding NuPathe's Migraine Patch in Complete Response Letter


    Quote:

    Quote
    CONSHOHOCKEN, PA, Aug 30, 2011 (MARKETWIRE via COMTEX) -- NuPathe Inc. PATH +11.26% today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the New Drug Application (NDA) for its migraine patch (NP101 or Zelrix). A CRL is issued by the FDA's Center for Drug Evaluation and Research when the review of an NDA is completed and questions remain that preclude the FDA from approving the NDA at the time.

    In the CRL, the Agency acknowledged that NuPathe established the efficacy of the migraine patch in the overall migraine population. The CRL primarily contained chemistry, manufacturing and safety questions, which the Company believes it has, or shortly will have, sufficient data to address. The Company may conduct additional Phase I and/or non-clinical studies to address other questions. NuPathe will request an End-of-Review meeting with the Agency to discuss the CRL and the Company's approach to resolving the outstanding issues. The issuance of this CRL means that the Company will not launch its migraine patch in the first half of 2012, as previously announced.


    "This CRL gives us confidence that we can provide the information needed to support FDA approval for our migraine patch in a timely manner," said Jane Hollingsworth, CEO of NuPathe. "We continue to believe that our patch will address the symptoms of millions of patients who suffer from debilitating migraine headache pain and migraine-related nausea. We look forward to working with the FDA to bring this important product to market."


    http://bit.ly/pmj5Fe


    mal sehn obs bounct


    Bookvalue 1.71$ Cash per share 2.46$

    bubble gum?